Hold onto your tie-dye shirts, because the government is officially getting into the psychedelic game. In a move that sounds like a plot twist from a 1960s movie, two Trump administration cabinet members have announced a brand-new partnership between the Department of Health and Human Services (HHS) and the Department of Veterans Affairs (VA). Their mission is to collaborate on the research and development of psychedelic medicines for individuals struggling with serious mental health conditions.
The two departments officially signed a memorandum of understanding (MOU) on Monday. This major step comes just months after President Donald Trump issued an executive order designed to expand and speed up research into the potential therapeutic benefits of psychedelics.
Preparing the VA for a Greener Future
So, what does this actually mean for veterans? The ultimate goal is to get the VA’s massive healthcare system ready to implement any psychedelic medicines that eventually score Food and Drug Administration (FDA) approval.
Under the new MOU, the HHS and VA will be tag-teaming a few key initiatives:
- Training Healthcare Professionals: They will work on clinical protocols and workforce training so therapists, nurses, and doctors are prepared to safely administer future FDA-approved, rapid-acting psychiatric drugs.
- Gathering Real-World Data: The partnership plans to collect and share data regarding the safety, effectiveness, and cost of these treatments to improve patient care and shape future policies.
- Building Scientific Evidence: Both departments will coordinate research and share evidence to help guide future FDA regulatory decisions and coverage rules.
Expanding the Psychedelic Push
The collaboration does not stop there. A second MOU was also announced on Monday, this time between the VA and the FDA. This specific agreement focuses on boosting information-sharing and scientific collaboration to further advance the development of psychedelic medicines.
According to National Institutes of Health Director Jay Bhattacharya, there is preliminary evidence that these types of therapies can essentially “rewire the brain,” offering rapid improvements for folks battling serious mental illness or substance use disorders. However, he did caution that there is still much to learn about the long-term risks and benefits, including the potential for misuse.
This entire initiative is part of a much larger push in Washington. Previously, the FDA and HHS announced steps in April to accelerate access to psychedelic therapies. In May, a bipartisan group of 32 lawmakers urged the FDA to speed up their reviews, and there is even a new bill floating around that would require the Department of Defense to evaluate how ongoing psilocybin research could help active military members.
Dabbin-Dad Newsroom
